OGN Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally...

Stats
Today's Volume	1.67M
Average Volume	2.07M
Market Cap	5.49B
EPS	$0 ( 2024-05-02 )
Next earnings date	( $0.930 ) 2024-06-04
Last Dividend	$0.280 ( 2024-05-10 )
Next Dividend	$0 ( N/A )
P/E	5.23
ATR14	$0.0140 (0.07%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-04	Morrissey Joseph T. Jr.	Buy	3 604	Common Stock
2024-05-04	Morrissey Joseph T. Jr.	Sell	1 568	Common Stock
2024-05-04	Morrissey Joseph T. Jr.	Sell	3 604	Restricted Stock Units
2024-05-04	Nisita Vittorio	Buy	2 078	Common Stock
2024-05-04	Nisita Vittorio	Sell	712	Common Stock

INSIDER POWER
71.82
Last 100 transactions
Buy: 1 855 517 \| Sell: 300 367

Volume Correlation

Long: 0.55 (weak)

Short: -0.88 (strong negative)

Signal:(60.446) Neutral

Organon & Co. Correlation

10 Most Positive Correlations
CACI	0.929
LDOS	0.902
TRIS	0.901
WAB	0.899
XYL	0.898
SF	0.896
BSX	0.892
TCOA	0.891
TRTL	0.891
HWM	0.886

10 Most Negative Correlations
LEG	-0.918
CHGG	-0.905
COUR	-0.892
TWI	-0.885
HTZ	-0.879
GPMT	-0.872
NVRO	-0.867
ARI	-0.861
CLDT	-0.861
WHR	-0.859

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Organon & Co. Correlation - Currency/Commodity

0.21
( neutral )

-0.02
( neutral )

0.00
( neutral )

0.20
( neutral )

-0.08
( neutral )

Organon & Co. Financials

Annual	2023
Revenue:	$6.26B
Gross Profit:	$3.75B (59.84 %)
EPS:	$4.01

FY	2023
Revenue:	$6.26B
Gross Profit:	$3.75B (59.84 %)
EPS:	$4.01

FY	2022
Revenue:	$6.17B
Gross Profit:	$3.88B (62.84 %)
EPS:	$3.61

FY	2021
Revenue:	$6.30B
Gross Profit:	$3.92B (62.21 %)
EPS:	$5.33

Financial Reports:

No articles found.

Organon & Co. Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.280 (N/A)	$0.280 (N/A)	$0.280 (N/A)	$0.280 (N/A)	$0.280 (N/A)	$0.280 (N/A)	$0.280 (N/A)	$0.280 (N/A)	$0 (N/A)	$0 (N/A)

Organon & Co. Dividend Information - Dividend King

Dividend Sustainability Score: 9.77 - good (97.73%) | Divividend Growth Potential Score: 4.51 - Stable (9.73%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.280	2021-08-20
Last Dividend	$0.280	2024-05-10
Next Dividend	$0	N/A
Payout Date	2024-06-13
Next Payout Date	N/A
# dividends	12	--
Total Paid Out	$3.36	--
Avg. Dividend % Per Year	3.61%	--
Score	5.21	--
Div. Sustainability Score	9.77
Div.Growth Potential Score	4.51
Div. Directional Score	7.14	--

Next Divdend (Est)
(2024-07-01)

$0.285 Estimate 71.67 %

Dividend Stability

0.96 Excellent

Dividend Score

5.21

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
2021	$0.560	1.68%
2022	$1.120	3.59%
2023	$1.120	3.99%
2024	$0.560	3.81%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend King	2023-06-30	Quarterly	2	5.23%	8.53
ARR	Dividend Royal	2024-05-14	Monthly	15	11.08%	8.50
ACV	Dividend Royal	2024-06-13	Monthly	10	10.19%	8.50
ACP	Dividend Royal	2024-05-22	Monthly	14	11.88%	8.50
PVL	Dividend Royal	2023-11-15	Monthly	14	9.37%	8.50
AVK	Dividend Royal	2024-05-14	Monthly	22	9.54%	8.31
AFG	Dividend Royal	2024-04-12	Bi-Monthly	39	9.39%	8.06
JPT	Dividend King	2023-11-02	Monthly	8	4.19%	8.05
VCIF	Dividend Royal	2023-08-18	Monthly	6	8.05%	8.02
EDI	Dividend Royal	2023-12-07	Monthly	13	8.85%	7.94

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.165	1.500	6.70	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0880	1.200	7.07	8.48	[0 - 0.3]
returnOnEquityTTM	-3.59	1.500	-10.00	-10.00	[0.1 - 1]
payoutRatioTTM	0.278	-1.000	7.22	-7.22	[0 - 1]
currentRatioTTM	1.649	0.800	6.76	5.41	[1 - 3]
quickRatioTTM	0.837	0.800	9.78	7.82	[0.8 - 2.5]
cashRatioTTM	0.226	1.500	9.86	10.00	[0.2 - 2]
debtRatioTTM	0.733	-1.500	10.00	-10.00	[0 - 0.6]
interestCoverageTTM	1.381	1.000	-0.599	-0.599	[3 - 30]
operatingCashFlowPerShareTTM	2.98	2.00	9.01	10.00	[0 - 30]
freeCashFlowPerShareTTM	1.987	2.00	9.01	10.00	[0 - 20]
debtEquityRatioTTM	181.54	-1.500	10.00	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.590	1.000	3.49	3.49	[0.2 - 0.8]
operatingProfitMarginTTM	0.114	1.000	9.71	9.71	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.0873	1.000	-0.626	-0.626	[0.2 - 2]
assetTurnoverTTM	0.534	0.800	9.77	7.82	[0.5 - 2]
Total Score				9.77

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	5.21	1.000	9.57	0	[1 - 100]
returnOnEquityTTM	-3.59	2.50	-10.00	-10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	1.987	2.00	9.34	10.00	[0 - 30]
dividendYielPercentageTTM	5.25	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	2.98	2.00	9.01	10.00	[0 - 30]
payoutRatioTTM	0.278	1.500	7.22	-7.22	[0 - 1]
pegRatioTTM	0.106	1.500	-2.63	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.120	1.000	9.50	0	[0.1 - 0.5]
Total Score				4.51

Organon & Co. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Organon & Co.

Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.

Realtime updates for Organon & Co. [OGN]

Upcoming Earnings Alert